TLR1 and pneumococcal infection: Collectively, this data supports the TLR1/2 agonist, Pam3CSK4, when combined with squalene emulsion, functions as a potent adjuvant to promote significantly increased production of PPS-specific Abs that provide protection against lethal pneumococcal infection relative to the non-adjuvanted vaccine in mice.